Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621738 | 0.73 | CTSS (0.33) | CTSS | |
| SCHEMBL2161282 | 0.69 | NPSR1 (0.33) | — | |
| SCHEMBL8744749 | 0.68 | GRM5 (0.31) | — | |
| SCHEMBL31254853 | 0.68 | EGLN2 (0.33) | — | |
| SCHEMBL8744737 | 0.68 | CTSK (0.47) | — | |
| SCHEMBL31521761 | 0.68 | GABRA1 (0.42) | — | |
| SCHEMBL15554408 | 0.67 | — | — | |
| SCHEMBL9959496 | 0.67 | — | — | |
| SCHEMBL2198117 | 0.67 | HSP90AA1 (0.38) | — | |
| SCHEMBL9958531 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840507-B2 | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, NV (BE) | 2017-12-12 | — | — | US | disclosed |
| US-9840507-B2 | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, NV (BE) | 2017-12-12 | — | — | US | disclosed |
| EP-2655376-B1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2655376-B1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-23 | — | — | EP | disclosed |
| CN-103403007-B | As 5,6-dihydro-imidazol-s also [1,2-a] pyrazine-8-yl amine derivatives of beta-secretase (BACE) inhibitor | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-12-09 | — | — | CN | disclosed |
| CN-103403007-A | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | disclosed |
| EP-2655376-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica NV (BE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012085038-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | CTSS 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.